Rhenman & Partners Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Rhenman & Partners Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.4M	Sell	63,050 -750	-1%	-$163K	1.46%	26
2026 Q1	$10.8M	Sell	63,800 -51,000	-44%	-$8.81M	1.33%	28
2025 Q4	$21M	Sell	114,800 -58,000	-34%	-$8.1M	1.96%	14
2025 Q3	$21M	Buy	172,800 +82,000	+90%	+$9.24M	2.32%	8
2025 Q2	$9.48M	Sell	90,800 -18,800	-17%	-$1.99M	1.2%	35
2025 Q1	$12.8M	Sell	109,600 -13,000	-11%	-$1.48M	1.47%	29
2024 Q4	$10.4M	Hold	122,600	–	–	1.07%	37
2024 Q3	$11M	Sell	122,600 -5,000	-4%	-$436K	0.89%	38
2024 Q2	$10.3M	Sell	127,600 -16,000	-11%	-$1.18M	0.99%	37
2024 Q1	$11.5M	Buy	143,600 +64,500	+82%	+$5.41M	1.09%	32
2023 Q4	$6.3M	Buy	79,100 +39,000	+97%	+$2.61M	0.63%	52
2023 Q3	$2.8M	Hold	40,100	–	–	0.3%	67
2023 Q2	$2.88M	Buy	40,100 +25,100	+167%	+$1.85M	0.3%	69
2023 Q1	$908K	Buy	+15,000	New	+$985K	0.1%	85

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Rhenman & Partners Asset Management's AXSM Position: Q2 2026 in Review

Rhenman & Partners Asset Management reduced its Axsome Therapeutics (AXSM) stake by 1.2% in Q2 2026, selling an estimated $163K and leaving 63,050 shares worth $15.4M. The position accounts for 1.46% of the portfolio, ranked #26.

Rhenman & Partners Asset Management first reported a position in AXSM in Q1 2023 and has held it in 14 quarters since. The position peaked at $21M in Q3 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Rhenman & Partners Asset Management held 63,050 shares of Axsome Therapeutics worth $15.4M as of Q2 2026.
Rhenman & Partners Asset Management sold 750 Axsome Therapeutics shares in Q2 2026, an estimated $163K.
Axsome Therapeutics made up 1.46% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #26 holding.
Rhenman & Partners Asset Management first reported a position in Axsome Therapeutics in Q1 2023 and has held it in 14 quarters since.
Rhenman & Partners Asset Management's Axsome Therapeutics position peaked at $21M in Q3 2025.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.